ORGO ReNu BLA Accepted: First Biologic for Knee OA

Organogenesis Holdings (ORGO) announced on July 6, 2026 that the FDA accepted its Biologics License Application (BLA) for ReNu, a cryopreserved amniotic suspension allograft for the treatment of pain in symptomatic knee osteoarthritis (OA). The FDA set a PDUFA target action date of April 24, 2027.

What ReNu is

ReNu is a regenerative medicine product consisting of amniotic fluid cells and micronized amniotic membrane, containing cellular, growth factor, and extracellular matrix components. It is administered as a single intra-articular injection. The FDA conditionally accepted Amnuvx (azimplacel) as the proprietary name, pending approval.

ReNu has been studied in three large randomized controlled trials enrolling more than 1,300 patients. It received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for knee OA in 2021. The product was previously marketed commercially for approximately six years under Section 361, which governs minimally manipulated human cellular and tissue-based products. The BLA filing moves ReNu from that lower regulatory pathway to full biologic drug approval.

Why this matters

Knee OA affects an estimated 31 million Americans, projected to exceed 34 million by 2027. There are no disease-modifying therapies. Current options are symptom management: NSAIDs, corticosteroid injections, hyaluronic acid injections, and total knee replacement at end stage. A regenerative allograft with Phase 3 RCT evidence would be the first biologic therapy specifically for knee OA.

The addressable market is large, but commercial success depends on reimbursement. Organogenesis will need Medicare and private payer coverage decisions after approval, and the PDUFA date is only the first regulatory step. Without coverage, a biologic injection for knee OA could face slow adoption among orthopedic practices.

Risk factors

The BLA filing is a binary catalyst for a $2.55 stock. Organogenesis is a small-cap regenerative medicine company with a primary business in advanced wound care, not a biotech with deep regulatory experience in the drug approval pathway. The FDA may require additional evidence before approval, and the transition from Section 361 marketing to full BLA approval carries higher evidentiary standards. Competing regenerative approaches for knee OA are in development, and any safety signal in the FDA review could delay or derail approval.

What to watch next

The FDA review timeline runs through April 2027. Watch for any FDA advisory committee meeting request, which would signal the agency has questions about the data. Reimbursement decisions from Medicare Administrative Contractors will follow any approval and determine commercial uptake.

ORGO closed at $2.55 on July 25, 2026.

Source: Organogenesis press release | GlobeNewswire